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Abstract
New strategies are needed to circumvent increasing outbreaks of resistant strains of pathogens and
to expand the dwindling supply of effective antimicrobials. A common impediment to drug
development is the lack of an easy approach to determine the in vivo mechanism of action and
efficacy of novel drug leads. Towards this end, we describe an unbiased approach to predict in
vivo mechanisms of action from NMR metabolomics data. Mycobacterium smegmatis, a non-
pathogenic model organism for Mycobacterium tuberculosis, was treated with 12 known drugs
and 3 chemical leads identified from a cell-based assay. NMR analysis of drug-induced changes to
the M. smegmatis metabolome resulted in distinct clustering patterns correlating with in vivo drug
activity. The clustering of novel chemical leads relative to known drugs provides a mean to
identify a protein target or predict in vivo activity.
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Emerging and remerging infectious disease outbreaks from numerous gram-negative and
grampositive pathogens have increased dramatically over the past decade.1 Further, we are
facing the serious likelihood that these pathogens will soon become resistant to all known
antibacterial treatments, which may lead to worldwide pandemics.2 Unfortunately, the
development and approval of antibiotics have not kept pace with the growing emergence of
resistant pathogens.3 Instead, there has been a decline in the approval of new antibiotics.4
Twenty novel classes of marketable antibiotics were produced between 1930 and 1962.5
These classes of antibiotics inhibit a short list of cellular processes: cell wall biosynthesis,
DNA supercoiling, transcription, translation and folate biosynthesis. Since 1962, only two
new antibiotic classes have received FDA approval: oxazolidinones, which inhibits protein
synthesis, and cyclic lipopeptides, which destroys membrane potential. Both compounds are
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used in the treatment of gram positive bacteria, such as methicillin-resistant Staphylococcus
aureus (MRSA).5 However, additional antibiotics are needed to combat the prevalence of
other multidrug resistant pathogens, such as Enterococcus faecium, Klebsiella pneumonia,
Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species that are
infecting the majority of US hospitals.6 Also extreme drug resistant strains of
Mycobacterium tuberculosis are a rising threat in the world.
The Infectious Diseases Society of America (IDSA) has proposed an initiative to develop
and approve 10 novel antibiotics by the year 2020.7 However, existing drug discovery
strategies may not be able to meet these challenges. Drug discovery programs rely heavily
on target based high throughput screening (HTS) of large chemical libraries followed by
lead optimization.8, 9 Unfortunately, this approach has demonstrated an extremely high rate
of failure and erroneous leads. Even when a valid HTS hit is found, it is uncertain if this
chemical lead can penetrate into the bacterial cell and demonstrate in vivo activity.
NMR Metabolomics is evolving as a significant component of the drug discovery process
and offers an inexpensive route to help overcome the multiple challenges faced by
researchers.10 Metabolomics is a relatively new field and is based on the identification and
quantification of small molecules found in living cells or biofluids.11 Since small molecules
are downstream products of biomolecular processes, the identity and concentration of
metabolites provide biochemical signatures for tracking the physiological effects of
antibiotic efficacy, selectivity, and toxicity. Characterizing these biochemical signatures
relies upon the global determination of numerous endogenous small molecules followed by
pattern recognition using multivariate analysis.12 Such comprehensive biochemical
information can be readily obtained using 1H NMR spectroscopy with minimal sample
handling while providing highly reproducible data in an automated fashion.10 Multivariate
statistical analysis, such as orthogonal partial least-squares discriminant analysis (OPLS-
DA), is typically employed to extract information from the large and complex NMR data
sets.13 Simply, OPLS-DA is used to identify clustering patterns from the major variations
between NMR spectra.10
Herein, we describe a new method using 1H NMR and OPLS-DA to profile the in vivo
mechanism of action of known antibiotics used to treat M. tuberculosis. More importantly,
we aim to use this information to classify compounds with unknown mechanisms of action,
but demonstrated anti-tubercular activity. Our approach is predicated on the hypothesis that
drugs with similar modes of activity or therapeutic targets will have a similar impact on the
metabolome of M. smegmatis and will cluster together in an OPLS-DA scores plot. Thus,
the mode of action of a novel chemical lead can be inferred from its clustering in an OPLS-
DA scores plot relative to drugs with defined biological targets. Importantly, if the chemical
lead is separated from known drugs in the OPLS-DA scores plot, then this result would infer
a new mechanism of action and a potentially valuable, new antibiotic.
Our methodology was demonstrated using 12 antibiotics known to inhibit the growth of M.
tuberculosis and M. smegmatis (Table 1). The mechanism of action for each antibiotic was
identified from the Drug Bank Database,14 and the minimum inhibitory concentrations
(MIC) were obtained from the scientific literature.15-23 In addition, three chemical leads
were randomly selected from the Tuberculosis Antimicrobial Acquisition and Coordinating
Facility (TAACF) library of compounds (http://www.TAACF.org). The compounds were
screened against M. tuberculosis and have comparable MICs to known TB drugs, but the
biological target or mechanism of action was not reported by TAACF. The non-pathogenic
M. smegmatis was used as a model system for the NMR metabolomics study.
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In order to analyze changes in the M. smegmatis metabolome, the drug dosage needs to be
below lethal levels and only affect cell growth. Typically, a drug concentration that inhibits
cell growth by approximately 50% of the growth rate of untreated cells is desirable. While
MIC values are available from the literature, these concentrations are based on standardized
drug gradients, inoculum sizes, and readout endpoints. Additionally, the reported MICs were
obtained with different bacterial strains, at different growth stages or cell densities, and
under a variety of experimental conditions that includes either broth or agar methods.
Further complicating the situation is the diversity of MICs values reported for a single drug.
Thus, the literature MIC values listed in Table 1 were simply used as a starting point to
determine an optimal dosage for the NMR metabolomics study under our experimental
conditions. Each drug was titrated over a concentration range of 1 to 24 times the literature
MIC values. The individual drug concentrations needed to achieve ~50% growth inhibition
are reported in Table 1. An average growth inhibition of 43.1 ± 10.5% was observed after
the addition of each of the 15 drugs. Preparation of the M. smegmatis cell cultures for
metabolomic analysis was then performed using the optimal dosage for each drug.
Due to the inherit variability of biological samples and to provide a robust statistical
analysis, 10 cultures inoculated with each antibiotic and 40 cultures of untreated cells were
prepared for the NMR metabolomics study. A 1D 1H NMR spectrum was collected for each
biological sample, which were normalized using center averaging and analyzed using
OPLS-DA. A representative 2D OPLS-DA scores plot displaying a comparison between 6
antibiotics with known mechanisms of action is shown in Figure 1. The OPLS-DA model
was cross-validated using a modified leave-one-out method. A quality assessment score (Q2)
of 0.82 was obtained, which is an excellent result compared to an ideal score of one. Thus,
the cross-validation indicates a highly reliable model. Each point in the 2D OPLS-DA scores
plot represents a single 1D 1H NMR spectrum of a specific drug treated or untreated cell
culture. The 2D OPLS-DA scores plot consists of 4 separate clustering patterns, which
demonstrates that each group has a considerably different impact on the metabolome of M.
smegmatis. Importantly, all the drug-treated M. smegmatis cell cultures form distinct and
separate clusters from the untreated cell cultures. This is consistent with all the drugs being
biologically active and inhibiting M. smegmatis cell growth.
Antibiotics that share a similar or identical biological target were observed to cluster
together in the OPLS-DA scores plot. For example, ethambutol and isoniazid inhibit
mycolic acid biosynthesis that prevents the formation of the arabinogalactan-mycolic acid
matrix. Streptomycin and ciprofloxacin form the second cluster. Streptomycin prevents
protein synthesis and ciprofloxacin inhibits DNA supercoiling that affects replication,
transcription, and repair, leading to a similar disruption in protein synthesis. Since these two
antibiotics cluster together, it implies that the inhibition of transcription or translation results
in a similar impact on the metabolome. Vancomycin and D-cycloserine both affect cell wall
formation and form the third cluster. In a principal component analysis (PCA) of the data
(see supplemental Figure 1S) there is a more pronounced separation between vancomycin
and D-cycloserine along PC2. This reflects a fundamental difference between PCA and
OPLS-DA, where PCA is limited to a linear model and does not readily differentiate
between within-class and between-class variations.13, 24 Correspondingly, OPLS-DA is
preferred as long as cross-validation verifies a reliable model.
The NMR metabolomics analysis was then expanded to include a total of 12 drugs with
known biological targets and 3 compounds randomly chosen from the TAACF library.
Amiodorone, clofazamine and chlorprothixene are active against TB, but have unknown
mechanisms of action according to the TAACF database. Nevertheless, the three compounds
are known drugs, where amiodorone is an antiarrhythmic agent that affects potassium efflux,
chlorprothixene is an antipsychotic drug that inhibits dopamine receptors, and clofazamine
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is a 40 year-old leprosy treatment with an ill-defined biological activity. The 2D OPLS-DA
scores plot (Figure 2A) identified 4 distinct clusters and yielded a highly reliable cross
validation Q2 score of 0.671. As before, the different clusters are correlated with distinct
modes of action: inhibition of cell wall formation, inhibition of mycolic acid biosynthesis,
and inhibition of transcription, translation or the overall effects of DNA supercoiling.
The accompanying metabolomics tree diagram25 (Figure 2B) clearly visualizes the relative
groupings of the three antibiotic classes. The bootstrap numbers of 89 to 100 indicate a
statistically significant separation between the five clusters and the reliability of the general
drug and TAACF classifications. The metabolic tree diagram also provides a finer
separation between the drugs within each cluster. These separations may reflect actual
differences in the specific drug targets. For example, D-cycloserine and vancomycin are on
separate branches in the cell wall node potentially because D-cycloserine inhibits alanine
racemase and alanine ligase compared to vancomycin binding the D-alanyl-D-alanine
dipeptide. Alternatively, the separation may result from differences in the relative activity of
the drug. Streptomycin forms a separate branch in the transcription, translation or DNA
supercoiling drug cluster despite having a similar target (binding to the 30S ribosomal
protein S12 and 16S rRNA) relative to other members within the cluster. But, streptomycin
is one of the most active compounds tested, requiring only a dosage of 1.5 μg/ml to inhibit
M. smegmatis growth by approximately 50%. Also, over-interpreting these subtle
separations may be erroneous since the within cluster differences may simply reflected
experimental variability and may not be biologically relevant. For instance, an average
growth inhibition of 43.1 ± 10.5% was observed after the addition of each of the 15 drugs.
This dosage variability may lead to unintended separations in the 2D OPLS-DA scores plot.
Essentially, the reliability of these finer cluster differences is dependent on additional
supportive biological data.
Surprisingly, amiodorone, chlorprothixene, and clofazamine were found to cluster together
in the 2D OPLS-DA scores plot and metabolic tree diagram. This was an unexpected result
given that the three compounds were randomly selected from the large TAACF library and
have diverse therapeutic usages. But, it also implies the three compounds share a similar
mechanism of action in TB. Importantly, the three TAACF compounds also cluster with the
antibiotics that disrupt cell wall formation, ampicillin, D-cycloserine and vancomycin. This
infers a similar mode of action between the three TAACF compounds and the antibiotics
that are known to interfere with bacterial cell walls. A subsequent literature search indicated
that the three TAACF compounds have been previously shown to disrupt bacterial
membranes in organisms distinct from TB.26-30 Thus, the literature results are consistent
with our NMR metabolomics analysis, which support our general classification of the
TAACF compounds as interfering with bacterial cell walls. It is important to note that while
ampicillin is a member of this class of antibiotics, it is also skewed toward the untreated
cells in the 2D OPLS-DA scores plot. Presumably, this is because of M. smegmatis β-
lactamase activity that provides resistance to ampicillin.23, 31 The impact of ampicillin on
the metabolome of M. smegmatis is significantly diminished such that ampicillin M.
smegmatis is similar to untreated cells. As described previously, there are some differences
between the OPLS-DA and PCA scores plot (see supplemental Figure 2S). There is less
discrimination between the untreated and drug treated cells in the 2D PCA scores plot. This
is not unexpected since PLS is preferred over PCA for discrimination been classes.24 Also,
there is a separation between the three TAACF compounds and the cell wall antibiotics in
the PCA scores plot, but the TAACF compounds are still closer to the cell wall antibiotics in
the associated metabolic tree diagram (see supplemental figure 2S). In fact, the OPLS-DA
and PCA metabolomic tree diagrams are quite similar despite these visible differences in the
scores plots. Additionally, the quality of the OPLS-DA model is apparent from the fit to the
data, R2X > 0.610 and R2Y > 0.803 and the reliability of the model is apparent from the
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cross-validation Q2 scores > 0.617. Further validation of the OPLS-DA drug and TAACF
classifications comes from the analysis of the metabolites identified as the major
contributors to the OPLS-DA class separation (see supplemental Figures 3S-6S).
The S-plots and loading plots determined from the OPLS-DA models identify the chemical
shifts (and associated metabolites) that contribute to the observed separation between the
untreated and treated cells in the 2D OPLS-DA scores plot. The metabolites and
corresponding pathways predominately perturbed by the addition of each drug class are
listed in supplemental Tables 1S- 3S. While there are some broad similarities in the
metabolites and pathways affected by the drugs because the comparisons are all made
relative to untreated cells, there are also some distinct differences. For example, proline,
cytidine, uridine and inosine (pyrimidine and purine pathways) are all uniquely decreased by
drugs that affect transcription, translation or DNA supercoiling. Obviously, nucleotides are
essential metabolic precursors to DNA and RNA synthesis. Alternatively, choline
phosphate, lysine, spermidine, citruline, ascorbate and dehydroascorbate
(glycerophospholipid, lysine biosynthesis, arginine and proline metabolism, and ascorbate
metabolism pathways) are decreased by drugs affecting the mycolic acid pathway.
Ascorbate metabolism is directly linked to the mycolic acid pathway, where ascorbate leads
to arabinose. Arabinose is the primary precursor for the arabinogalactan-mycolic acid
complex. Also, the inhibition of spermidine synthesis has been previously observed for
drugs targeting the mycolic acid pathway in mycobacteria.32 Importantly, the set of
metabolites affected by the TAACF compounds were identical to metabolites perturbed by
D-cycloserine and vancomycin. Both show a decrease in oxaloacetate, glutamine, glutamate,
methionine and folate and an increase in isoleucine. Clearly, amino acids and their
precursors are important components in peptidoglycan, cell wall and cell membrane
synthesis. There were some additional metabolites that are increased by the addition of D-
cycloserine and vancomycin that were not observed with the TAACF compounds. These
include other amino acids (alanine, lysine serine, valine) and other precursors to
peptidoglycan synthesis (N-acetyl-D-glucosamine, N-acetylneuraminate). Overall, the
identity of the specific metabolites perturbed by each drug class is consistent with the 2D
OPLS-DA scores plot clustering pattern and drug classifications.
In conclusion, we have demonstrated that different classes of antibiotics uniquely affect the
metabolome of M. smegmatis. These metabolomic changes are directly correlated with
broad mechanisms of action that are associated with each TB class of antibiotics, disruption
of cell walls or membranes, inhibition of transcription, translation or DNA supercoiling, or
the inhibition of mycolic acid biosynthesis. Thus, NMR metabolomics provides an efficient,
simple and unbiased approach for providing rapid classification of promising drugs leads
that emerge from HTS. This is critical since HTS does not provide any information on
mechanisms of action; only relative activity with a high-false positive rate. Instead, the in
vivo biological activity of a novel lead can be inferred by its relative clustering to existing
drug classes in an OPLS-DA scores plot derived from metabolomics data. Importantly, a
chemical lead that forms a distinct cluster from known drugs infers a potential new
mechanism of action and a reason to prioritize the chemical lead for a detailed follow-up
investigation. Of course, the induced metabolomic changes relative to untreated cells
provide further confirmation of in vivo efficacy, which was implied from the HTS results.
While the technique was demonstrated with M. smegmatis, it is generally applicable to
bacterial pathogens and the effect of therapeutic agents on human cell lines in addition to the
analysis of biofluids.
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METHODS
Determining Optimal Drug Dosage for NMR Metabolomics Experiments
M. smegmatis mc2155 cells were grown at 37 °C with shaking at 200 rpm in 50 mL of
Middlebrook 7H9 media until an average optical density at 600 nm (O.D.600) of 0.6 was
achieved. Each drug was titrated over a concentration range of 1 to 24 times the literature
MIC values and the cells were grown for an additional 2 hours. The optical density was
recorded and the growth rate inhibition was calculated by comparing the optical density of
the treated cells to the untreated cells in the 2 hour time period. The desired drug dosage was
determined where a drug concentration inhibits cell growth by approximately 50% of the
growth rate of untreated cells.
Sample Preparation—A total of 190 M. smegmatis mc2155 cultures were grown in 50
mL of Middlebrook 7H9 at 37 °C with shaking at 200 rpm until an O.D.600 of 0.6 was
achieved. A total of 40 untreated cultures were used as a control and 10 cultures were
inoculated with each antibiotics at the optimal dosage needed to inhibit cell growth by ~50%
as described in Table 1. The cells were then grown for an additional 2 hours. The used
media was removed and the cells were washed 3 times and resuspended with 1 mL ice cold
double distilled water. The cells were lysed using a FastPrep-24 instrument for 60 seconds at
6 m/s, and the supernatant was extracted and frozen in a dry ice ethanol bath. The samples
were lyophilized and then resuspended with 700 μL of 99.8% D2O solution containing 50
mM phosphate buffer (pH 7.2, uncorrected) and 50 μM 3-(trimethylsilyl)propionic
acid-2,2,3,3-d4 (TMSP-d4) as an internal standard for chemical shift referencing. The
samples were then centrifuged for 5 minutes to remove any insoluble material, and 600 μL
of the supernatant was transferred to an NMR tube.
NMR Data Collection and Processing
The NMR spectra were collected on a Bruker 500 MHz Avance spectrometer equipped with
a triple resonance and z axis gradient cryoprobe. A BACS-120 sample changer was used for
automated data collection. 1D 1H NMR spectra were collected using excitation sculpting to
remove the solvent signal and maintain a flat spectral baseline.33 A total of 32K data points
with a spectral width of 5482.5 Hz, 16 dummy scans and 128 scans were used to obtain each
spectrum. The data was processed automatically using ACD/1D NMR Manager (Advanced
Chemistry Development). Intelligent bucketing was used to integrate each spectral region
with a bin size of 0.025 ppm. Each NMR spectrum was center averaged to minimize any
experimental variations between bacterial cultures as follows:34
(1)
where X̄ is the average signal intensity, σ is the standard deviation in the signal intensity, and
Xi is the signal intensity within a bin. Noise regions of the spectra were omitted from the
PCA analysis by setting the corresponding bins to zero.35
OPLS-DA and PCA was performed using Simca-11.5+ (Umetrics), where each 1H NMR
spectra was reduced to a single point in the 2D OPLS-DA and PCA scores plot. The OPLS-
DA was calculated with two classes, untreated versus drug treated cell cultures, for the Y
matrix with the NMR data incorporated into the X matrix. The OPLS-DA model was cross
validated using a modified version of the leave-one-out technique, where 1 out of every 7
samples (spectra) were left out to calculate a model and predict the left out data.36 The
procedure was sequentially repeated leaving out a different 1/7th of the data. The predicted
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data was then compared to the original data, where the quality assessment (Q2) score
provides a qualitative measure of the predictability of the model based on the consistency
between the predicted and original data. An ideal value for Q2 is one, where a typical value
for a biological model is ≥ 0.4.
Metabolomic Tree diagrams with corresponding bootstrap values were created using our
PCAtoTree program to interpret the OPLS-DA clustering pattern.25 The metabolomics tree
diagram is based on the Euclidean distances between the cluster centers from the 2D OPLS-
DA scores plot. Standard bootstrapping techniques are used to generate a set of 100 distance
matrices by randomly re-sampling the cluster centers and Euclidean distances. The set of
100 distance matrices are then used by PHYLIP (http://www.phylip.com),37 phylogenetic
software package, to generate 100 tree diagrams and a consensus tree diagram. The
bootstrap numbers on the consensus tree diagram indicates the number of times each node
was present in the set of 100 tree diagrams, where a bootstrap number below 50% indicates
a generally insignificant node or insignificant separation between the clusters.
Four additional OPLS-DA models were generated to identify specific metabolites associated
with drug activity: (i) inhibition of translation, transcription or DNA supercoiling drug
treated cells versus untreated cells, (ii) inhibition of mycolic acid synthesis drug treated cells
versus untreated cells, (iii) inhibition of cell wall synthesis drug treated cells versus
untreated cells, and (iv) the three TAACF compounds versus untreated cells. S-plots and
loading plots were generated from each OPLS-DA model. Bins (chemical shift values)
demonstrating a covariance of greater than 0.10 or less than -0.10 were identified as major
contributors to the class separation. Metabolites were identified from this list of chemical
shifts using the Human Metabolome Database (HMDB, http://www.hmdb.ca/)38 with a
chemical shift tolerance of 0.02 ppm. Metabolic network maps were then generated using
Cytoscape (http://www.cytoscape.org/)39 with the MetScape40 plugin for the top 100
metabolite predicted by HMDB. Metabolites were excluded if not part of a network or not
present in M. smegmatis.
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Figure 1.
2D OPLS-DA scores plot demonstrating the clustering pattern obtain for six different
antibiotics with known and distinct biological targets: untreated M. smegmatis cells (■),
ciprofloxacin ( ), streptomycin ( ), ethambutol ( ), isoniazid ( ), D-cycloserine ( ),
and vancomycin ( ) treated M. smegmatis cells. The ellipses correspond to the 95%
confidence limits from a normal distribution for each cluster. The untreated M. smegmatis
cells (■) was designated the control class and the remainder of the cells were designated as
treated. The OPLS-DA used one predictive component and three orthogonal components to
yield a R2X of 0.610, R2Y of 0.893 and Q2 of 0.82.
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Figure 2.
(a) 2D OPLS-DA scores plot demonstrating the clustering pattern for 12 antibiotics with
known biological targets and three compounds of unknown in vivo activity: untreated M.
smegmatis cells (■), chloramphenicol ( ), ciprofloxacin ( ), gentamicin ( ), kanamycin
( ), rifampicin ( ), streptomycin ( ), ethambutol ( ), ethionamide ( ), isoniazid ( ),
ampicillin ( ), D-cycloserine ( ), vancomycin ( ), amiodorone ( ), chlorprothixene
( ), and clofazimine ( )treated M. smegmatis cells. The ellipses correspond to the 95%
confidence limits from a normal distribution for each cluster. The untreated M. smegmatis
cells (■) was designated the control class and the remainder of the cells were designated as
treated. The OPLS-DA used one predictive component and six orthogonal components to
yield a R2X of 0.715, R2Y of 0.803 and Q2 of 0.671. (b) Metabolomics tree diagram
determined from the OPLS-DA scores plot. The coloring scheme for each compound in the
tree diagram correlates with the data point colors in the OPLS-DA scores plot. The bootstrap
numbers for each node are indicated on the tree diagram.
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Table 1
Description of antimicrobial compounds and dosages used in this study.
Compound Class Mechanism of Action MICa (μg/ml) Dosageb (μg/ml)
Ampicillin Penicillins Inhibits transpeptidation and prevents cell wall formation. 16.0c 96.0
Chloramphenicol Amphetamines Inhibits protein synthesis by binding to the 50S ribosomal
subunit.
6.0 6.0
Ciprofloxacin Fluoroquinolones Inhibits DNA gyrase and prevents DNA supercoiling. 0.2 2.0
D-cycloserine Oxazolidinones Inhibits alanine racemase and alanine ligase and prevents
cell wall formation (different from other oxazolidinones
that inhibit protein synthesis).
750 750
Ethambutol Amino Alcohols Disrupts arabinogalactan formation by inhibiting arabinosyl
transferase.
10.0 100.0
Ethionamide Pyridine Derivatives Inhibits mycolic acid formation similar to isoniazid. 20.0 160.0
Gentamicin Aminoglycosides Inhibits protein synthesis by binding to the 30S ribosomal
protein S12 and 16S rRNA.
2.0 8.0
Isoniazid Pyridine Derivatives A prodrug that inhibits InhA and prevent mycolic acid
synthesis.
2.0 48.0
Kanamycin Aminoglycosides Inhibits protein synthesis by binding to the 30S ribosomal
protein S12 and 16S rRNA.
4.0 4.0
Rifampicin Rifampicins Inhibits RNA polymerase and prevent RNA synthesis. 30.0 60.0
Streptomycin Aminoglycosides Inhibits protein synthesis by binding to the 30S ribosomal
protein S12 and 16S rRNA.
0.25 1.5
Vancomycin Glycopeptides Binds to the D-alanyl-D-alanine dipeptide and prevents cell
wall formation.
50 450
Amiodarone Benzofurans Unknown 26.6 212.8
Clofazimine Anilines Unknown 0.32 3.84
Chlorprothixene Thioxanthines Unknown 36.0 216.0
a
Literature values of minimum inhibitory concentrations against M. smegmatis used as a starting point to determine an optimal dosage for the
NMR metabolomics study.
b
Actual dosage used to treat M. smegmatis cells to inhibit growth by ~50% following drug treatment.
c
Reported for M. smegmatis β-lactamase and ribosomal protein S12 mutants.
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Figure 1S: PCA scores plot demonstrating the clustering pattern of 6 different classes of known 
antibiotics: untreated M. smegmatis cells (■), ciprofloxacin (♦), streptomycin (♦), ethambutol (▼), 
isoniazid (▼), D-cycloserine (▲),  and vancomycin (▲) treated M. smegmatis cells. The ellipses 
correspond to the 95% confidence limits from a normal distribution for each cluster.   
   
Figure 2S: a) PCA scores plot demonstrating clustering patterns of 12 antibiotics with known mechanisms and 3 compounds that are unknown: 
untreated M. smegmatis cells (■), chloramphenicol (♦), ciprofloxacin (♦), gentamicin (♦), kanamycin (♦), rifampicin (♦), streptomycin (♦), 
ethambutol (▼), ethionamide (▼), isoniazid (▼), ampicillin (▲), D-cycloserine (▲), vancomycin (▲), amiodorone (●), chlorprothixene (●), 
and clofazimine (●)treated M. smegmatis cells. The ellipses correspond to the 95% confidence limits from a normal distribution for each cluster. 
b) Tree diagram of the PCA scores plot.  The coloring scheme for each compound in the tree diagram represents the data points in the scores plot. 
The bootstrap numbers for each node are indicated on the tree diagram. 
  
   
a) 
b) 
Figure 3S: a) OPLS-DA S-plot comparing the M. smegmatis treated with antibiotics known to 
inhibit Transcription or translation and untreated cell cultures.  Each point in the S-plot represents 
a specific bin containing a chemical shift range of about 0.25ppm, and the range varied by 50% 
using intelligent binning in the ACD 1D NMR processor. b) OPLS-DA loading plot comparing the 
M.smegmatis treated with antibiotics known to inhibit transcription or translation and untreated 
cell cultures. 
   
Table 1S.  Metabolites perturbed from drugs affecting transcription, translation or DNA supercoiling. 
Pathway Metabolite HMDB Score
a
 Relative Change
b
 
Glycolysis Glucose-6-Phosphate 19/50 + 
 Fructose-6-Phosphate 15/37 + 
 Glycerol-3-phosphate 18/34 + 
 Lactate 2/2 - 
Aminosugar N-Acetyl-D-glucosamine 23/50 + 
 N-Acetyl-Neuraminate 12/37 + 
Folate metabolism Folate 10/33 + 
Glycine, Serine, Threonine metabolism Serine 5/12 + 
Cysteine, Methionine metabolism Methionine 18/22 + 
TCA Citrate 2/4 + 
 Isocitrate 6/16 + 
 Acetoacetate 1/2 + 
Branched Chain Amino Acids Isoleucine 7/42 - 
 Leucine 5/25 - 
Alanine, Aspartate, Glutamate 
metabolism 
Alanine 2/6 - 
 Glutamate 12/30 + 
 Glutamine 16/28 + 
Lysine Biosynthesis Lysine 5/41 - 
Proline Metabolism Proline 8/44 - 
Pyrimidine Cytidine 7/25 - 
 Uridine 5/26 - 
Purine Inosine 4/21 - 
a
Number of peaks in query that matches the number of peaks in the Human Metabolome Database. Peaks in the 
query can be matched multiple times 
b
Relative change of metabolite concentration in drug treated cultures 
compared to untreated cultures. 
   
a) 
b) 
Figure 4S: a) OPLS-DA S-plot comparing the M. smegmatis treated with antibiotics known to 
inhibit mycolic acid pathways and untreated cell cultures. OPLS-DA loading plot comparing the 
M.smegmatis treated with antibiotics known to inhibit mycolic acid pathways and untreated cell 
cultures.  
 
   
Table 2S. Metabolites perturbed from drugs affecting Mycolic Acid pathways. 
Pathway Metabolite HMDB Score
a
 Relative Change
b
 
Gluconeogenesis Glucose-1-Phosphate 16/38 + 
Glycolysis Fructose-6-Phosphate 15/37 + 
 Oxalacetate 1/1 + 
 Lactate 2/6 + 
TCA Acetoacetate 1/2 + 
 2-Oxoglutarate 3/6 + 
 Isocitrate 6/16 + 
Aminosugar Arabinose 15/40 + 
Alanine, Aspartate, Glutamate metabolism GABA 6/11 + 
 Glutamate 12/30 + 
 Asparagine 5/12 - 
 Alanine 2/6 - 
Glycine, Serine, Threonine metabolism 2-Ketobutyrate 3/7 + 
 Homoserine 12/44 - 
Branched Chain Amino Acids Valine 2/16 + 
 Leucine 3/25 + 
Pyrimidine Orotate 1/1 + 
 Ureidopropionate 6/7 + 
Glycerophospholipid Choline Phosphate 8/15 - 
Lysine Biosynthesis Lysine 15/47 - 
Arginine and Proline metabolisim Spermidine 7/21 - 
 Citrulline 16/44 - 
Ascorbate metabolism Ascorbate 6/16 - 
 Dehydroascorbate 10/35 - 
a
Number of peaks in query that matches the number of peaks in the Human Metabolome Database. Peaks in the query 
can be matched multiple times 
b
Relative change of metabolite concentration in drug treated cultures compared to 
untreated cultures. 
   
a) 
b) 
Figure 5S: a) OPLS-DA S-plot comparing the M. smegmatis treated with antibiotics known to 
inhibit cell wall synthesis and untreated cell cultures.  b) OPLS-DA loading plot comparing the 
M.smegmatis treated with antibiotics known to inhibit transcription or translation and untreated 
cell cultures.  
 
   
Table 3S. Metabolites perturbed from drugs interfering with cell wall. 
Pathway Metabolite HMDB Score
a
 Relative Change
b
 
Glycolysis Glucose-6-Phosphate 19/50 + 
 Fructose-6-Phosphate 20/37 + 
 Oxaloacetate 1/1 - 
Aminosugar N-Acetyl-D-Glucosamine 25/50 + 
 N-Acetylneuraminate 12/37 + 
Alanine, Aspartate, Glutamate metabolism Alanine 2/6 + 
 GABA 8/11 + 
 Glutamine 18/28 - 
 Glutamate 18/30 - 
Branched Chain Amino Acids Valine 10/16 + 
 Isoleucine 31/42 + 
Glycine, Serine, Threonine metabolism Serine 7/12 + 
 2-Ketobutyrate 3/7 + 
Cysteine, Methionine metabolism Methionine 15/22 - 
Lysine Biosynthesis Lysine 15/47 + 
Folate metabolism Folate 13/33 - 
a
Number of peaks in query that matches the number of peaks in the Human Metabolome Database. Peaks in 
the query can be matched multiple times 
b
Relative change of metabolite concentration in drug treated cultures 
compared to untreated cultures. 
   
a) 
b) 
Figure 6S: a) OPLS-DA S-plot comparing the M. smegmatis treated with antibiotics with unkown 
mechanism and untreated cell cultures.  b) OPLS-DA loading plot comparing the M.smegmatis 
treated with antibiotics with unkown mechanism and untreated cell cultures.  
a) 
 Table 4S. Metabolites perturbed from drugs of unknown function. 
Pathway Metabolite HMDB Score
a
 Relative Change
b
 
Glycolysis Oxaloacetate 1/1 - 
Alanine, Aspartate, Glutamate metabolism Glutamine 20/28 - 
 Glutamate 25/30 - 
Branched Chain Amino Acids Isoleucine 20/42 + 
Cysteine, Methionine metabolism Methionine 15/22 - 
Folate metabolism Folate 24/33 - 
a
Number of peaks in query that matches the number of peaks in the Human Metabolome Database. Peaks in 
the query can be matched multiple times 
b
Relative change of metabolite concentration in drug treated 
cultures compared to untreated cultures. 
